Liver cancer is the second most common cause of cancer-related deaths worldwide. In 2021, it is estimated that more than 42,000 people will be diagnosed with the disease and approximately 30,000 will die because...
The FDA grants authorization for an e-cigarette for the first time, citing the benefits for people switching from traditional cigarettes, and more from Cancer Today magazine.
THE FDA APPROVED THE FIRST ADJUVANT IMMUNOTHERAPY FOR EARLY LUNG CANCER The U.S. Food and Drug Administration (FDA) granted expanded approval to atezolizumab (Tecentriq) to include the treatment of certain patients with early non-small...
On Wednesday, the American Association for Cancer Research (AACR) released its annual Cancer Progress Report. Now in its 11th year, the report details advances in the cancer research continuum, provides a comprehensive review of anticancer drugs, diagnostic tools, and devices approved by the U.S. Food and Drug Administration in the past year, shines a...
THE FDA APPROVED THE IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN COMBINATION AND AS A SINGLE AGENT FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with chemotherapy,...
THE FDA APPROVED A NEW TYPE OF CANCER INHIBITOR FOR CERTAIN PATIENTS WITH A HIGH RISK OF RECURRENCE The U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) with endocrine therapy for certain patients...
study shows the cost of drugs that manage cancer-related symptoms adds up, and more news of the week from Cancer Today magazine.
As the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved got underway on Wednesday, a trio of keynote speakers provided different perspectives on this critical field of research. The...
Researchers create breast cancer prediction models tailored for Asian Americans.
MRI can be a cost-effective way to screen for breast cancer, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More